These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 35976852)
1. Quantifying benefits of the Danish transfat ban for coronary heart disease mortality 1991-2007: Socioeconomic analysis using the IMPACTsec model. Bjoernsbo KS; Joensen AM; Joergensen T; Lundbye-Christensen S; Bysted A; Christensen T; Fagt S; Capewell S; O'Flaherty M PLoS One; 2022; 17(8):e0272744. PubMed ID: 35976852 [TBL] [Abstract][Full Text] [Related]
2. Explaining trends in coronary heart disease mortality in different socioeconomic groups in Denmark 1991-2007 using the IMPACTSEC model. Joensen AM; Joergensen T; Lundbye-Christensen S; Johansen MB; Guzman-Castillo M; Bandosz P; Hallas J; Prescott EIB; Capewell S; O'Flaherty M PLoS One; 2018; 13(4):e0194793. PubMed ID: 29672537 [TBL] [Abstract][Full Text] [Related]
3. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study. Marklund M; Zheng M; Veerman JL; Wu JHY PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090 [TBL] [Abstract][Full Text] [Related]
4. Quantifying the Socio-Economic Benefits of Reducing Industrial Dietary Trans Fats: Modelling Study. Pearson-Stuttard J; Critchley J; Capewell S; O'Flaherty M PLoS One; 2015; 10(8):e0132524. PubMed ID: 26247848 [TBL] [Abstract][Full Text] [Related]
5. Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. Hotchkiss JW; Davies CA; Dundas R; Hawkins N; Jhund PS; Scholes S; Bajekal M; O'Flaherty M; Critchley J; Leyland AH; Capewell S BMJ; 2014 Feb; 348():g1088. PubMed ID: 24503058 [TBL] [Abstract][Full Text] [Related]
6. The contribution of primary prevention medication and dietary change in coronary mortality reduction in England between 2000 and 2007: a modelling study. Guzman-Castillo M; Ahmed R; Hawkins N; Scholes S; Wilkinson E; Lucy J; Capewell S; O'Flaherty M BMJ Open; 2015 Jan; 5(1):e006070. PubMed ID: 25613952 [TBL] [Abstract][Full Text] [Related]
7. Can legal restrictions of prenatal exposure to industrial trans-fatty acids reduce risk of childhood hematopoietic neoplasms? A population-based study. Specht IO; Huybrechts I; Frederiksen P; Steliarova-Foucher E; Chajes V; Heitmann BL Eur J Clin Nutr; 2019 Feb; 73(2):311-318. PubMed ID: 30297761 [TBL] [Abstract][Full Text] [Related]
8. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. Allen K; Pearson-Stuttard J; Hooton W; Diggle P; Capewell S; O'Flaherty M BMJ; 2015 Sep; 351():h4583. PubMed ID: 26374614 [TBL] [Abstract][Full Text] [Related]
9. Analysing recent socioeconomic trends in coronary heart disease mortality in England, 2000-2007: a population modelling study. Bajekal M; Scholes S; Love H; Hawkins N; O'Flaherty M; Raine R; Capewell S PLoS Med; 2012; 9(6):e1001237. PubMed ID: 22719232 [TBL] [Abstract][Full Text] [Related]
10. Explaining the decline in coronary heart disease mortality rates in the Slovak Republic between 1993-2008. Psota M; Bandosz P; Gonçalvesová E; Avdičová M; Bucek Pšenková M; Studenčan M; Pekarčíková J; Capewell S; O'Flaherty M PLoS One; 2018; 13(1):e0190090. PubMed ID: 29320517 [TBL] [Abstract][Full Text] [Related]
11. Trans fatty acids and cholesterol levels: An evidence map of the available science. Liska DJ; Cook CM; Wang DD; Gaine PC; Baer DJ Food Chem Toxicol; 2016 Dec; 98(Pt B):269-281. PubMed ID: 27394654 [TBL] [Abstract][Full Text] [Related]
12. The Health Equity and Effectiveness of Policy Options to Reduce Dietary Salt Intake in England: Policy Forecast. Gillespie DO; Allen K; Guzman-Castillo M; Bandosz P; Moreira P; McGill R; Anwar E; Lloyd-Williams F; Bromley H; Diggle PJ; Capewell S; O'Flaherty M PLoS One; 2015; 10(7):e0127927. PubMed ID: 26131981 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. Pearson-Stuttard J; Hooton W; Critchley J; Capewell S; Collins M; Mason H; Guzman-Castillo M; O'Flaherty M J Public Health (Oxf); 2017 Sep; 39(3):574-582. PubMed ID: 27613767 [TBL] [Abstract][Full Text] [Related]
14. Denmark's Policy on Artificial Trans Fat and Cardiovascular Disease. Restrepo BJ; Rieger M Am J Prev Med; 2016 Jan; 50(1):69-76. PubMed ID: 26319518 [TBL] [Abstract][Full Text] [Related]
15. Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Young F; Capewell S; Ford ES; Critchley JA Am J Prev Med; 2010 Sep; 39(3):228-34. PubMed ID: 20709254 [TBL] [Abstract][Full Text] [Related]